Similar articles

• Re: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

  Vakaet L. Vakaet L. J Natl Cancer Inst. 2006 Aug 16;98(16):1162; author reply 1162-3. doi: 10.1093/jnci/djj323. J Natl Cancer Inst. 2006. PMID: 16912269 No abstract available.
• The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.

  Pennery E. Pennery E. Eur J Oncol Nurs. 2008 Jul;12(3):233-43. doi: 10.1016/j.ejon.2008.01.007. Epub 2008 Mar 26. Eur J Oncol Nurs. 2008. PMID: 18372213 Review.
• Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.

  Aapro M. Aapro M. Anticancer Drugs. 2008 Mar;19 Suppl 2:S1. doi: 10.1097/01.cad.0000277610.08129.06. Anticancer Drugs. 2008. PMID: 18337639 No abstract available.
• [Extended adjuvant hormone therapy (in breast cancer): Why? To whom? What? How long?].

  Kahán Z. Kahán Z. Magy Onkol. 2008 Jun;52(2):225-6. doi: 10.1556/MOnkol.52.2008.2.11. Magy Onkol. 2008. PMID: 18640899 Hungarian. No abstract available.
• Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.

  Baumann CK, Castiglione-Gertsch M. Baumann CK, et al. Minerva Ginecol. 2009 Dec;61(6):517-39. Minerva Ginecol. 2009. PMID: 19942839 Review.